# Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

> **NCT01624766** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 57 (actual)

## Conditions studied

- Advanced Malignant Neoplasm
- Metastatic Malignant Neoplasm
- Recurrent Malignant Neoplasm
- Refractory Malignant Neoplasm

## Interventions

- **BIOLOGICAL:** Anakinra
- **BIOLOGICAL:** Denosumab
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01624766
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-19
- **Primary completion:** 2021-02-24
- **Final completion:** 2021-02-24
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2021-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624766, "Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01624766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*